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Dear Editor,
A 49-year-old woman presented with stage IA diffuse large B
cell lymphoma (DLBCL) of the uterine cervix. She received
four courses of R-CHOP (rituximab, cyclophosphamide,
adriamycin, vincristine, and prednisolone) and two cycles of
R-ICE (rituximab, ifosfamide, carboplatin, and etoposide),
followed by local tomotherapy. A complete remission was
achieved, as shown by 18F-fluorodeoxyglucose positron
emission tomography–computed tomography (PET/CT).
However, she developed gradually numbness over her
right thoracic 10 dermatome. A magnetic resonance imaging
(MRI) scan performed 4 months later showed abnormal
signal intensity in the anterior and posterior wall of the
lower thoracic cord, at the origin of cauda equina and at
the anterior and posterior nerve roots of right thoracic
10 and thoracic 11 roots, suggestive of leptomeningeal
deposits. Lumbar puncture showed normal cerebrospinal
fluid, and although a dose of intrathecal methotrexate
and cytarabine was given there was no symptomatic
improvement.
On referred 6 months after the onset of neurologic symp-
toms, another MRI focusing on the thoracic spine showed
abnormal signal intensity in the anterior and posterior wall of
the lower thoracic cord at the origin of cauda equina and at the
anterior and posterior right thoracic 10 and thoracic 11 nerve
roots (Fig. 1a, arrow). To resolve the nature of the lesion, a
PET/CT scan was performed. It showed a hypermetabolic
soft tissue nodule (standardized uptake value maximum,
4.2) extending across the right thoracic 10/11 neural foramen
(Fig. 1b, arrow), suggesting a lymphomatous lesion.
The surgical resection specimen showed the presence of
atypical lymphoid cells among the neuroganglion tissue,
which were CD20+, CD3−, and BCL-2+ (Fig. 2a–d). The
overall features were consistent with DLBCL relapsing as
neurolymphomatosis.
Neurolymphomatosis refers to direct lymphomatous in-
filtration of the cranial and peripheral nerve and roots [1–3].
It is a very rare condition, with a recent study identifying
merely 50 patients from 12 centers in 5 countries over a 16-
year period [3]. Four different clinical presentations have
been described: painful infiltration of nerves or roots; cra-
nial neuropathy with or without pain; painless involvement
of peripheral nerves; and painful or painless involvement of
a single peripheral nerve [1]. Aggressive B cell lymphoma is
the predominant underlying pathology [1–3]. Owing to the
nonspecific presentation, the diagnosis is often delayed.
Furthermore, biopsies are not feasible when deep-seated
roots or cranial nerves are involved. Hence, when neurologic
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symptoms are the initial manifestation, the diagnosis of neuro-
lymphomatosis may not be made until at post-mortem [1–3].
In a patient with a history of lymphoma, the diagnostic
challenge is to distinguish neurolymphomatosis from other
pathologies not due to direct nerve invasion, including lep-
tomeningeal lymphoma, nerve compression from adjacent
lymphoma masses, neuropathy related to chemotherapy and
radiotherapy, lymphoma-associated vasculitis, and paraneo-
plastic syndromes [2]. Imaging studies are therefore very
helpful in these differential diagnoses. Earlier studies have
relied on MRI, which might not be able to distinguish
between lymphomatous or a primary nervous tissue lesion.
As shown in the present study, PET/CT allows the lesion to
be accurately localized and gives an indication of the met-
abolic activity of the lesion [4], which provides useful
information on the differential diagnosis of the nature of
the pathology.
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Fig. 2 Histopathology of neuro-
lymphomatosis. a Surgical spec-
imen showing neuroganglion
tissue diffusely infiltrated by ab-
normal lymphoid cells (hema-
toxylin–eosin). b Lymphoid
cells were positive for CD20
(immunoperoxidase stain). c
Lymphoid cells were negative
for CD3. d Lymphoid cells were
positive for BCL-2
a bFig. 1 Imaging studies in neuro-lymphomatosis. a MRI scan
showing a lesion (arrow) at the
anterior and posterior right tho-
racic 10 and thoracic 11 nerve
roots. b Positron emission
tomography/computed tomogra-
phy, showing an isolated hyper-
metabolic lesion in the right
thoracic tenth foramen (arrow)
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